Clixint Technologies DPI 'showseries' Parameter Cross Site Scripting Vulnerability
BID:51734
Info
Clixint Technologies DPI 'showseries' Parameter Cross Site Scripting Vulnerability
| Bugtraq ID: | 51734 |
| Class: | Input Validation Error |
| CVE: |
CVE-2012-0975 |
| Remote: | Yes |
| Local: | No |
| Published: | Jan 31 2012 12:00AM |
| Updated: | Feb 06 2012 01:20PM |
| Credit: | Red Security TEAM |
| Vulnerable: | |
| Not Vulnerable: | |
Discussion
Clixint Technologies DPI 'showseries' Parameter Cross Site Scripting Vulnerability
DPI is prone to a cross-site scripting vulnerability because it fails to properly sanitize user-supplied input.
An attacker may leverage this issue to execute arbitrary script code in the browser of an unsuspecting user in the context of the affected site. This may let the attacker steal cookie-based authentication credentials and launch other attacks.
DPI 1.3 is vulnerable; other versions may also be affected.
DPI is prone to a cross-site scripting vulnerability because it fails to properly sanitize user-supplied input.
An attacker may leverage this issue to execute arbitrary script code in the browser of an unsuspecting user in the context of the affected site. This may let the attacker steal cookie-based authentication credentials and launch other attacks.
DPI 1.3 is vulnerable; other versions may also be affected.
Exploit / POC
Clixint Technologies DPI 'showseries' Parameter Cross Site Scripting Vulnerability
Attackers can exploit this issue by enticing an unsuspecting user to follow a malicious URI.
Attackers can exploit this issue by enticing an unsuspecting user to follow a malicious URI.
Solution / Fix
Clixint Technologies DPI 'showseries' Parameter Cross Site Scripting Vulnerability
Solution:
Currently we are not aware of any vendor-supplied patches. If you feel we are in error or if you are aware of more recent information, please mail us at: [email protected].
Solution:
Currently we are not aware of any vendor-supplied patches. If you feel we are in error or if you are aware of more recent information, please mail us at: [email protected].